

Press Release



PI-01-2008

Insilico Biotechnology AG in collaboration with Kluuyver Centre for Genomics of Industrial Fermentation

Insilico expands collaboration with Kluuyver Centre for Genomics of Industrial Fermentation

(Stuttgart, Delft) – Insilico Biotechnology AG announces a continued collaboration with the Netherlands' Kluuyver Centre, a joint industry and academic consortium that applies genomics technology for improving industrial fermentation. The Stuttgart based company provides its new steady state and dynamic modeling and simulation platform for the set-up and analysis of predictive metabolic network models.

The Department of Biotechnology at Delft University of Technology, a partner in the Kluuyver Centre aims at improving the efficiency of bioprocesses by focussing on microbial performance. Its Bioprocess Technology section has broad experience in modelling both bioreactor systems and metabolic networks. More recently, the research interest has shifted towards developing new experimental hardware, analytical protocols and theoretical tools that allow the *in vivo* analysis of the responses of microbial cells to environmental and genetic disturbances. The new tools are applied to study the metabolic reaction networks and control structures in *Saccharomyces cerevisiae* and *Penicillium chrysogenum*. The research currently focuses on central carbon metabolism of these two industrially relevant strains. Professor Heijnen, heading the BioprocessTechnology group in the Kluuyver Centre, explained, »We needed a research partner able to support the set-up and simulation of large-scale dynamic *in silico* metabolic network models«.

The Bioprocess Technology group will use »Insilico Discovery« to reconstruct and validate metabolic network models by integrating metabolomic and flux data. Moreover, the Bioprocess Technology group will use Insilico's newly developed non-stationary ¹³C tracer analysis tool for observing intracellular flux distributions.

»We are proud to collaborate with this outstanding research consortium«, said Klaus Mauch, CEO of Insilico Biotechnology AG. Insilico currently supports several European research groups aiming at the development of metabolic network models. Klaus Mauch added, »Our computational solutions serve a growing need for integrated and predictive methods to fully exploit a systems biology approach«.

Press Release



Insilico Biotechnology predicts and optimizes biotechnological processes for the chemical, food, agro, and healthcare industries. Successful in business since 2001, Insilico provides internationally renowned expertise and unique technology platforms. Insilico's competitive advantage is its proven track record of producing new insights and IP for customers in systems biology using its proprietary software, databases and computing facilities. By building better and innovative integrated models of complex cellular processes, Insilico sets new standards in systems biology as a leading solution provider to the Life Sciences industries. Insilico's expertise derives from several research laboratories and the company's co-founders. Insilico is a privately-owned company, located in Stuttgart, Germany.

The Kluyver Centre for Genomics of Industrial Fermentation is a consortium of Delft University of Technology, Wageningen University and Research Centre, Leiden University, Nijmegen University, Utrecht University, TNO, Wageningen Centre for Food Sciences, Agrotechnology and Food Sciences Group and NIZO food research. It employs microbial genomics to improve microorganisms for use in industrial fermentation processes. Fermentation is used in the production, from renewable feedstocks, of food products and ingredients, beverages, pharmaceutical compounds, nutraceuticals, and fine and bulk chemicals. The research covers six programmes: yeast fermentation, fungal fermentation, lactic acid fermentation, biocatalysis, genomics tools including bioinformatics and society and genomics. For more information about the Kluyver Centre, please visit: www.kluyvercentre.nl.

Contact:

Insilico Biotechnology AG
Klaus Mauch | CEO
T +49 711 674 2164
F +49 711 674 2166
klaus.mauch@insilico-biotechnology.com
www.insilico-biotechnology.com

Kluyver Centre
Dr. Walter van Gulik
T +31 15 2784629
F +31 15 2782355
w.m.vangulik@tnw.tudelft.nl
www.kluyvercentre.nl

Disclaimer:

The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.